

WATSON PHARMACEUTICALS INC  
Form 8-K  
August 10, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**August 4, 2010**

**WATSON PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

**Nevada  
(State or Other Jurisdiction  
of Incorporation)**

**001-03305  
(Commission File Number)**

**95-3872914  
(IRS Employer  
Identification No.)**

**311 Bonnie Circle  
Corona, California 92880  
(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (951) 493-5300**

**(Former name or former address, if changed since last report): Not applicable.**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of an Officer.**

On August 4, 2010, Watson Pharmaceuticals, Inc. (the Company ) announced that Thomas R. Russillo would be succeeded by Sigurdur Oli Olafsson as Executive Vice President, Global Generics, effective September 1, 2010.

Mr. Russillo will retire from the Company at the end of 2010.

The news release announcing Mr. Russillo's retirement and Mr. Olafsson's appointment is attached hereto as Exhibit 99.1

---

**Item 9.01. Financial Statements and Exhibits.**

Exhibit No.	Exhibit
99.1	Press Release issued by Watson Pharmaceuticals, Inc. on August 4, 2010.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2010

WATSON PHARMACEUTICALS, INC.

By: /s/ David A. Buchen

Name: David A. Buchen

Title: Senior Vice President,  
General Counsel and Secretary

---

**EXHIBIT INDEX**

Exhibit No.	Exhibit
99.1	Press Release issued by Watson Pharmaceuticals, Inc. on August 4, 2010.